Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 2—February 2021

Zika Virus–Associated Birth Defects, Costa Rica, 2016–2018

Adriana Benavides-LaraComments to Author , María de la Paz Barboza-Arguello, Mauricio González-Elizondo, Marcela Hernández-deMezerville, Helena Brenes-Chacón, Melissa Ramírez-Rojas, Catalina Ramírez-Hernández, Nereida Arjona-Ortegón, Shana Godfred-Cato, Diana Valencia, Cynthia A. Moore, and Alejandra Soriano-Fallas
Author affiliations: Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud, Cartago, Costa Rica (A. Benavides-Lara, M.P. Barboza-Arguello, M. González-Elizondo); Caja Costarricense del Seguro Social, San José, Costa Rica (M. Hernández-deMezerville, H. Brenes-Chacón, C. Ramírez-Hernández, N. Arjona Ortegón, A. Soriano-Fallas); Ministry of Health, San José (M. Ramírez-Rojas); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S. Godfred-Cato, D. Valencia, C.A. Moore)

Cite This Article


CME Logo


In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at; and (4) view/print certificate.

Release date: January 21, 2021; Expiration date: January 21, 2022
Learning Objectives

Upon completion of this activity, participants will be able to:

  • Describe epidemiologic features and prevalence of Zika-related birth defects (ZBD) and microcephaly among live-born infants in Costa Rica, March 2016 to March 2018, according to a descriptive analysis

  • Determine clinical and test findings of live-born infants with ZBD in Costa Rica, March 2016 to March 2018, according to a descriptive analysis

  • Identify clinical and public health implications of features of ZBD among live-born infants in Costa Rica, March 2016 to March 2018, according to a descriptive analysis.

CME Editor

P. Lynne Stockton Taylor, VMD, MS, ELS(D), Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: P. Lynne Stockton Taylor, VMD, MS, ELS(D), has disclosed no relevant financial relationships.

CME Author

Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.


Disclosures: Adriana Benavides-Lara, MD, MSc; María de la Paz Barboza Arguello, MSc; Mauricio González Elizondo, MSc; Marcela Hernández-de Mezerville, MD; Helena Brenes-Chacón; Alejandra Soriano, MD; Melissa Ramírez Rojas, MD, MSc; Nereida Arjona Ortegón, MD; Catalina Ramírez-Hernández, MD, MSc; Shana Godfred-Cato, DO; Diana Valencia, MS; and Cynthia A. Moore, MD, PhD, have disclosed no relevant financial relationships.



After Zika virus (ZIKV) infection in Costa Rica was confirmed in January 2016, the national surveillance system was enhanced to monitor associated birth defects. To characterize the ZIKV outbreak among live-born infants during March 2016–March 2018, we conducted a descriptive analysis. Prevalence of ZIKV-associated birth defects was 15.3 cases/100,000 live births. Among 22 infants with ZIKV-associated birth defects, 11 were designated as confirmed (positive for ZIKV) and 11 were designated as probable cases (negative for ZIKV or not tested, but mother was expsed to ZIKV during pregnancy). A total of 91% had microcephaly (head circumference >2 SDs below mean for age and sex), 64% severe microcephaly (head circumference >3 SDs below mean for age and sex), 95% neurodevelopmental abnormalities, 82% brain anomalies, 41% eye abnormalities, and 9% hearing loss. Monitoring children for >1 year can increase identification of ZIKV-associated abnormalities in addition to microcephaly.

Zika virus (ZIKV) is an RNA virus of the Flaviviridae family and is transmitted primarily by mosquitos of the genus Aedes (Stegomyia). The virus was discovered in Uganda in 1947 (1) and isolated from humans in Nigeria in 1953; in subsequent years, small clusters of infection in humans from Africa and Asia were reported (2). ZIKV outbreaks were identified in Yap in 2007 and in French Polynesia in 2013–2014 (24). In 2015, ZIKV reached the continental Americas, and an outbreak in Brazil was identified (5). In September 2015, an increased number of children were born with microcephaly and other central nervous system (CNS) defects in countries where ZIKV was circulating (68).

An article published in early 2017 described the most severe phenotype of ZIKV-associated birth defects (ZBD) (9). The 5 key characteristics of that phenotype are severe microcephaly with collapse of the skull and redundancy of the scalp consistent with the fetal brain disruption sequence (10), thinning of the cerebral cortex and subcortical calcifications, macular scarring with focal retinal pigment mottling, congenital joint contractures, and hypertonia with symptoms of extrapyramidal involvement. These findings were noted to be more characteristic of ZIKV infection than other congenital infections; however, they did not constitute a case definition. Several subsequent studies supported that these defects were associated with ZIKV infection during pregnancy (1113).

In Costa Rica, microcephaly has been monitored by the national birth defects surveillance system (NBDSS) since 1985. Before the ZIKV epidemic, Costa Rica was among countries with the highest prevalence of microcephaly in Latin America; microcephaly prevalence during 2011–2015 was 4.2 cases/10,000 live births (95% CI 3.6–4.9 cases/10,000 live births; n = 153; annual median 31) (14). In January 2016, the National Virology Reference Center (Cartago, Costa Rica), in coordination with the NBDSS, implemented laboratory-based surveillance for ZIKV disease; in February 2016, the NBDSS, along with health authorities, initiated ZBD surveillance (Figure 1). To characterize the effects of the Zika virus outbreak on live-born infants, we reviewed enhanced surveillance data for birth defects and the clinical characteristics of infants with confirmed and probable ZBD born in Costa Rica during March 2016–March 2018. In accordance with the Costa Rican Biomedical Research Legislation, Article 7, the analysis of surveillance data was registered in the National Council of Health Investigation.


Birth Defects Surveillance System

We conducted a descriptive analysis based on retrospective data collected for the NBDSS during the study period. The Costa Rican Birth Defects Register Center is an NBDSS that collects information on internal and external ZBD for all live-born infants up to 1 year of age. Passive reporting is mandatory for public and private hospitals; live-birth coverage is 96%. In February 2016, birth defect surveillance was enhanced by creation of a protocol that established the follow-up of cases, including laboratory tests for ZIKV and other differential diagnoses (18). Cases reported to the NBDSS were reviewed and classified by a multidisciplinary team in Costa Rica and by subject matter experts from the US Centers for Disease Control and Prevention.


Microcephaly is defined as head circumference measurement >2 SDs below the mean for a given age and sex (19); it is severe when the circumference is >3 SDs below the mean for a given age and sex. For infants born at term, we used World Health Organization growth charts (20). For preterm infants, microcephaly was defined as head circumference below the third percentile according to the Fenton Growth Charts ( Congenital and postnatal-onset microcephaly were included.

Suspected Cases

All potential cases of birth defects were reported to NBDSS. These reports were reviewed to determine whether they met the criteria for a suspected case of birth defects. Suspected cases were those that met >1 of the following criteria:

• Live-born infants with microcephaly, regardless of laboratory findings in the mother or infant, or maternal symptoms of ZIKV (rash and fever) during pregnancy

  • Any live-born infant with >2 of the following findings (or 1 + microcephaly), regardless of laboratory findings in the mother or infant or maternal ZIKV symptoms during pregnancy:

    • CNS: intracerebral calcifications, cerebellar hypoplasia, thinning of the cerebral cortex, corpus callosum anomalies, ventriculomegaly or increased extra-axial fluid, abnormal pattern of cerebral gyri (e.g., polymicrogyria, lissencephaly), and specific neurodevelopmental findings (e.g., psychomotor development delay, spasticity, persistent irritability, seizures, swallowing disorders, movement abnormalities, or extrapyramidal changes)

    • Sensorineural deafness

    • Eye: structural abnormalities (e.g., microphthalmia, coloboma, cataracts or intraocular calcifications; posterior pole anomalies such as chorioretinal atrophy, optic nerve abnormalities, focal retinal pigment mottling)

    • Arthrogryposis or multiple joint contractures affecting >1 major joint or talipes equinovarus

  • Live-born infants without microcephaly but with any major birth defect not consistent with a ZBD (e.g., significant cardiac defect) or with specific neurodevelopmental findings mentioned above, born to a mother with probable or confirmed ZIKV infection during pregnancy (defined as a mother with symptomatic ZIKV infection during pregnancy and/or a strong epidemiologic link to ZIKV during pregnancy [lives in high ZIKV–endemic area or has close contact with ZIKV–positive person] with or without positive laboratory test result for ZIKV during pregnancy)

For all suspected case-patients, a serum sample, urine sample, or both were collected from the infant before hospital discharge. Samples were tested for ZIKV RNA by using established singleplex real-time reverse transcription PCR (rRT-PCR) (3). Serum was tested in parallel with Zika IgM Antibody Capture ELISA (3,21). The NBDSS was immediately notified, the case was reviewed, and the infant was referred to a pediatrician and the congenital infection clinic (CIC). A multidisciplinary assessment of the child was conducted and included evaluation by pediatricians and the CIC; laboratory testing for syphilis, toxoplasmosis, rubella, and cytomegalovirus infection; cranial ultrasonography; and indirect ophthalmologic examination and neonatal auditory screening by otoacoustic emissions, followed by auditory brainstem response. Referral to a geneticist, pediatric cardiologist, neurodevelopmental specialist, or pediatric neurologist was dependent on examination findings. Thus, some of the children underwent complementary testing such as chromosomal or fluorescence in situ hybridization analysis, cardiac or abdominal ultrasonography, computerized tomography, and specialized neurodevelopmental assessments.

Classification and Characterization of Suspected Cases

All clinical, epidemiologic, and laboratory data for suspected cases were reviewed. Cases were classified as confirmed, probable, excluded, and not classifiable (Figure 2) as follows:

• Confirmed case-patients were infants with ZBD (clinical criteria) for whom a sample taken before hospital discharge was positive for ZIKV by rRT-PCR or IgM ELISA (laboratory criteria) and who had an epidemiologic link (mother with ZIKV symptoms or was ZIKV positive by rRT-PCR during pregnancy or was from a highly ZIKV–endemic community).

• Probable case-patients were infants with ZBD (clini­cal criteria) who had negative ZIKV results by rRT-PCR or IgM ELISA or were not tested but whose mother had laboratory-confirmed ZIKV infection or symptoms compatible with ZIKV infection or had an epidemiologic link, and no other cause for the birth defect was identified.

• Excluded case-patients were infants with ZBD not related to ZIKV infection, who had negative laboratory results for ZIKV by rRT-PCR and IgM ELISA or were not tested and whose mother had negative ZIKV results, no symptoms of ZIKV infection, or no clear exposure to ZIKV during pregnancy. Excluded cases also included infants who had other known etiologies for microcephaly or the birth defect or had a presumed syndrome of undetermined cause. This group also included infants with a diagnosis of microcephaly at birth whose head circumference by 1 year of age was <2 SDs below the mean (and did not have any other birth defects).

• Not classifiable case-patients were in infants with insufficient information to be appropriately included in the previous categories.


We calculated population-based birth prevalence and 95% CI for confirmed and probable cases of ZBD and microcephaly during the period of enhanced surveillance and compared the prevalence ratio for microcephaly with the baseline prevalence during 2011–2015. We also calculated the distributions of specific birth defects and neurodevelopmental abnormalities among infants with ZBD. Total births for the period were obtained from the National Institute of Statistics and Censuses ( To characterize infants with ZBD, we used the mother’s province of origin; mother’s history of exposure to ZIKV during pregnancy (associated symptoms or laboratory confirmation); and the infant’s head circumference, weight, length, gestational age, ZIKV molecular and serologic test results, other reported birth defects, and neurodevelopmental anomalies.


Of 373 potential cases reported to the NBDSS, 243 met the criteria for a suspected case (Figure 2); 150 (62%) of the 243 infants were female. Compared with microcephaly baseline data for Costa Rica (22), the birth prevalence of microcephaly increased from 4.2 (95% CI 3.6–4.9) cases/10,000 live births during 2011–2015 to 15.5 (95% CI 13.5–17.5) cases/10,000 live births during the Zika outbreak (March 2016–March 2018); prevalence ratio was 3.7 (95% CI 3.0–4.5).

Evaluation of Suspected ZBD Cases

A pediatric infectious disease specialist at the CIC examined 40% (96/243) of the infants with suspected ZBD >1 time; a pediatrician evaluated the rest. The most frequent birth defect was microcephaly; 88% (213/243) had microcephaly at birth. Among those, 26% (55/213) had severe microcephaly. Postnatal-onset microcephaly developed in 5% (12/243), and no microcephaly but other criteria that met the definition of suspected ZBD was found for 7% (18/243). A total of 9% (22/243) of suspected cases-infants were classified as having confirmed or probable ZBD, 84% (204/243) were excluded, and 7% (17/243) were not classifiable (Table 1; Figure 2).

For 79% (193/243) of newborns, >1 ZIKV laboratory test was performed by urine or serum rRT-PCR or by serum IgM ELISA. Cerebrospinal fluid from 4 infants was available for testing. Serologic tests for other congenital infections were completed for syphilis (65%, 159/243), rubella (87%, 211/243), cytomegalovirus infection (69%, 168/243), and toxoplasmosis (68%, 166/243).

Among infants with suspected ZBD, 68% (165/243) underwent head ultrasonography or computed tomography (CT), 56% (136/243) underwent indirect ophthalmologic evaluation, 46% (113/243) had hearing screened by otoacoustic emissions, and 31% (75/243) underwent auditory brain response testing. Diagnostic auditory brain response testing was also performed for those with confirmed and probable cases.

Confirmed and Probable Cases of ZIKV-Associated Birth Defects

The prevalence of ZBD during March 2016–March 2018 was 15.3 (95% CI 8.9–21.7) cases/100,000 live births, based on 22 confirmed and probable cases among 143,930 live births (Figure 3). Proportion of deaths within the first year of life among infants with ZBD was 13.6% (3/22). All death cases were classified as probable. These infants had cerebral anomalies, microcephaly, hypertonia, multiple joint contractures (n = 2), and optic nerve hypoplasia (n = 1), and were born to immigrant mothers from highly ZIKV-endemic areas.

Most infants with ZBD were full-term newborns (95%, 21/22) and had weight appropriate for gestational age (68%, 15/22). The average weight (± SD) at birth was 2,818 g (± 657 g, range 1,560–3,940 g), and height was 44.2 cm (± 3.1 cm, range 41–53 cm). Eleven infants classified as confirmed cases were positive for ZIKV (9 by IgM ELISA and 2 by IgM ELISA and rRT-PCR; Figure 2); among 11 infants classified as having probable cases, 7 had negative test results (4 by rRT-PCR and IgM ELISA and 3 by rRT-PCR alone) and 4 did not undergo laboratory testing.

The provinces registering the highest prevalence of ZBD were Limón (58.8 cases/100,000 live births) and Puntarenas (37.1 cases/100,000 live births) (Figure 4). Among mothers of infants with ZBD, 64% had symptoms, 27% during the first trimester and 37% during the second trimester; 23% of the mothers had positive ZIKV rRT-PCR results during pregnancy (Table 2). Among infants with ZBD, 91% (20/22) had microcephaly (Table 3); onset was postnatal for 9% (2/22 cases). Two infants who did not have microcephaly were born to mothers who had confirmed ZIKV infection during the second trimester of pregnancy. One of these infants had cortical atrophy seen with head ultrasonography, scarring of the macula, strabismus, central hypotonia and peripheral hypertonia, swallowing difficulties, epilepsy and global neurodevelopmental delay; the other infant had normal brain images and neurodevelopment, but atrophic scarring involved the macula of both eyes.

Head ultrasonography was performed for 21 of the 22 infants classified as confirmed and probable ZBD (6 of them also underwent CT, magnetic resonance imaging, or both), and the other underwent head CT. Among these infants, 82% (18/22) had evidence of >1 brain defect. Those without brain defects evident by imaging had defects in the eye, body tone, or neurodevelopment.

Ophthalmologic evaluation was performed for 91% (20/22) of infants classified as having confirmed and probable cases; eye anomaly was detected for 45% (9/20). Sensorineural deafness was present in 9% (2/22); however, only 15/22 (68%) underwent audiologic evaluation with diagnostic auditory brain response testing. At least 1 neurodevelopmental anomaly was present in 95% (21/22) of infants; most (82%) had body tone anomalies (mainly hypertonia or spasticity) and possible neurodevelopmental delay. Other frequent manifestations included multiple contractures, seizures, movement anomalies, swallowing anomalies, and possible visual impairment (strabismus, nystagmus, or failure to fix and follow).


In Costa Rica, most infants with ZBD were born ≈1 year after the onset of autochthonous circulation of ZIKV and 6 months after peak incidence of ZIKV infection among pregnant women. Similar findings have been observed in Brazil, Colombia, and the United States, where the peak incidence was observed ≈6 months after the ZIKV epidemic, corroborating a temporal link between ZIKV infection and associated birth defects (7,23,24). Most infants with ZBD were born to mothers who reported symptoms in the first and second trimesters of pregnancy (64%), consistent with other reports (2529); however, because 36% were born to mothers who were asymptomatic, the proportion of infections in early to mid-pregnancy is probably greater.

The birth prevalence of infants with confirmed and probable ZBD during the enhanced surveillance period was 15.3 (95% CI 8.9–21.7) cases/100,000 live births. Birth prevalence of microcephaly, which was monitored before the ZIKV outbreak in Costa Rica, increased by almost 4-fold after the ZIKV outbreak, from 4.2 cases/10,000 live births to 15.5 cases/10,000 live births. Although we recognize that the birth prevalence of this defect may be underreported during non–ZIKV-epidemic times, these data are consistent with the experience in other countries, where the prevalence of microcephaly increased >4-fold (Colombia, French Polynesia, United States) (7,24,25) and up to 9-fold (Brazil) (30,31). Heightened awareness of the possible association between congenital ZIKV infection and microcephaly, as well as country-specific protocols to improve identification of this traditionally underascertained birth defect, probably contributed to increased prevalence estimates (32). Additional efforts were necessary to differentiate microcephaly as a component of ZBD from microcephaly from other causes in Costa Rica and in other ZIKV-affected locations. Consistent with published case series from Brazil (11,12) and from the US Zika Pregnancy and Infant Registry (26), we found that the most frequent clinical finding was microcephaly and most cases were classified as severe. The percentage of brain abnormalities was similar to what has been published (11,26,33), and among infants who underwent neuroimaging, the most common findings were ventriculomegaly and cerebral calcifications, consistent with results of a recent meta-analysis (34). Two case-patients did not have microcephaly; both were born to mothers who had confirmed ZIKV infection during the second trimester of pregnancy, and both had other clinical findings consistent with congenital ZIKV infection. These findings have also been reported in studies from Brazil (33), where up to 1 in 5 infants with confirmed or probable ZBD had a normal head circumference (12).

Anomalies of the eye have also been associated with congenital ZIKV infection. Among the infants with eye anomalies in our study, most common were anomalies of the fundus, primarily chorioretinal scars or abnormal macular pigmentation and papillary/optic nerve atrophy. Several case series reported the same findings for 24%–55% of case-patients (9), mainly children of mothers infected with ZIKV during the first trimester (35,36). ZIKV-associated eye defects were found without microcephaly in 10/24 (42%) infants born to mothers with rRT-PCR–confirmed ZIKV infection during pregnancy; 8 (33%) of these infants had no abnormal brain findings (36), consistent with what we found for 1 infant with a confirmed case.

Sensorineural deafness was detected in 13% of infants by diagnostic auditory brain response testing. One study that specifically evaluated hearing loss in children with birth defects found sensorineural deafness in 6% by using auditory brain response testing (37); most cases also had neurodevelopmental anomalies previously described in the literature (912,26,38). The most frequent neurodevelopmental anomalies were tone abnormalities (primarily hypertonia), movement anomalies, and congenital joint contractures. Some neurologic and developmental alterations associated with microcephaly are secondary to CNS damage caused by ZIKV. Described in our case series and in other studies, these alterations include movement abnormalities and posturing (50%), swallowing abnormalities (41%), and epilepsy (36%) (39).

Our descriptive analysis is subject to limitations. Findings are based on a passive surveillance system enhanced with confirmation of the diagnosis; thus, information depends on the completeness of reporting, case ascertainment, and workup of suspected cases to verify microcephaly and determine which cases are probably ZIKV associated. The NBDSS collects data on live births only; findings are not generalizable to stillbirths and miscarriages. Comparing the prevalence of ZBD among countries is difficult because surveillance system methods and definitions of microcephaly and suspected cases vary and evaluations and criteria used to define ZBD might differ substantially (40). Another consideration is the known limitations of ZIKV laboratory tests (4143). Among infants with ZBD, 50% had a positive ZIKV laboratory test result, all by ZIKV IgM ELISA and only 1 by rRT-PCR. Nonspecific reactivity resulting in a false-positive IgM result might have led to misclassification of cases as confirmed; however, false-positive IgM results seem unlikely, given the timing of ZIKV testing in these infants. Eleven infants with ZBD but without laboratory evidence were classified as probable cases. Of these, 7 had negative results by rRT-PCR, IgM ELISA, or both. The low detection of laboratory evidence for ZIKV infection in these infants probably reflects recognized challenges of laboratory testing, including the unknown sensitivity and specificity of testing of infants (41,42). In addition, given possible cross-reactivity for other flaviviruses and the need to prioritize resources, we did not conduct plaque-reduction neutralization tests. To help address laboratory limitations, we used the combination of clinical, epidemiologic, and laboratory data to classify cases. However, we cannot exclude an alternate etiology for birth defects in infants classified as probable cases.

The Pan American Health Organization recommends surveillance of ZIKV disease in pregnant women and monitoring outcomes of infants born with brain anomalies (44). Many countries have implemented surveillance to monitor infants of ZIKV-positive mothers to capture cases of ZBD, to determine the risk for birth defects, and to examine neurodevelopmental anomalies (25,30,32). Population-based birth defects surveillance programs along with monitoring pregnant women with ZIKV disease provide an example of a complementary approach to ascertaining exposures and outcomes to better monitor new and emerging threats during pregnancy and effects on infants (45). Costa Rica National Guidelines established laboratory sampling and monitoring of every child born to symptomatic women (46). In our analysis, 23% of mothers of infants with confirmed and probable ZBD had a positive laboratory test result for ZIKV (Table 2); had the enhanced birth defects surveillance system not been implemented, 77% of cases would not have been linked to ZIKV. In addition, 60%–80% of ZIKV infections are asymptomatic, and in Costa Rica, the laboratory test for ZIKV is performed only for symptomatic pregnant women. Given these challenges, the benefit of combining an intensified birth defects surveillance system with surveillance of pregnant women with laboratory-confirmed ZIKV infection, as was done in Costa Rica and Colombia (29), is very useful, especially for countries with few resources.

The success of surveillance for ZBD in Costa Rica depended on the strict application of standard operating procedures and the active participation of healthcare personnel to enhance ascertainment of component anomalies, such as microcephaly, and to identify infants with sufficient evidence of a confirmed or probable ZIKV etiology for their birth defects. Thus, global establishment and strengthening of NBDSS is essential, as recommended by the World Health Organization at its 63rd World Health Assembly (Resolution WHA63.17, Microcephaly is not the only congenital anomaly that should be monitored after ZIKV infection; other birth defects, such as congenital brain and eye defects and joint contractures, should also be monitored. Monitoring children born to ZIKV-positive mothers and those with ZBD or neurodevelopmental anomalies through at least the first years of life can increase identification of additional associated abnormalities such as deafness, eye or vision anomalies, postnatal onset of microcephaly, and substantial neurodevelopmental abnormalities. Other neurodevelopmental disabilities might become apparent after 1 year of age; thus, following children to 3 years of age is valuable and may enhance surveillance of ZBD and neurodevelopmental outcomes in Costa Rica.



  1. Dick  GWA, Kitchen  SF, Haddow  AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46:50920. DOIPubMedGoogle Scholar
  2. Petersen  LR, Jamieson  DJ, Powers  AM, Honein  MA. Zika Virus. N Engl J Med. 2016;374:155263. DOIPubMedGoogle Scholar
  3. Lanciotti  RS, Kosoy  OL, Laven  JJ, Velez  JO, Lambert  AJ, Johnson  AJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008;14:12329. DOIPubMedGoogle Scholar
  4. Aubry  M, Teissier  A, Huart  M, Merceron  S, Vanhomwegen  J, Roche  C, et al. Zika virus seroprevalence, French Polynesia, 2014–2015. Emerg Infect Dis. 2017;23:66972. DOIPubMedGoogle Scholar
  5. Campos  GS, Bandeira  AC, Sardi  SI. Zika virus outbreak, Bahia, Brazil. Emerg Infect Dis. 2015;21:18856. DOIPubMedGoogle Scholar
  6. Schuler-Faccini  L, Ribeiro  EM, Feitosa  IM, Horovitz  DD, Cavalcanti  DP, Pessoa  A, et al.; Brazilian Medical Genetics Society–Zika Embryopathy Task Force. Possible association between Zika virus infection and microcephaly—Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:5962. DOIPubMedGoogle Scholar
  7. Cuevas  EL, Tong  VT, Rozo  N, Valencia  D, Pacheco  O, Gilboa  SM, et al. Preliminary report of microcephaly potentially associated with Zika virus infection during pregnancy—Colombia, January–November 2016. MMWR Morb Mortal Wkly Rep. 2016;65:140913. DOIPubMedGoogle Scholar
  8. Kleber de Oliveira  W, Cortez-Escalante  J, De Oliveira  WT, do Carmo  GM, Henriques  CM, Coelho  GE, et al. Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed Zika virus transmission during the first trimester of pregnancy—Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:2427. DOIPubMedGoogle Scholar
  9. Moore  CA, Staples  JE, Dobyns  WB, Pessoa  A, Ventura  CV, Fonseca  EB, et al. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clincians. JAMA Pediatr. 2017;171:28895. DOIPubMedGoogle Scholar
  10. Russell  LJ, Weaver  DD, Bull  MJ, Weinbaum  M, Opitz  JM. In utero brain destruction resulting in collapse of the fetal skull, microcephaly, scalp rugae, and neurologic impairment: the fetal brain disruption sequence. Am J Med Genet. 1984;17:50921. DOIPubMedGoogle Scholar
  11. Del Campo  M, Feitosa  IML, Ribeiro  EM, Horovitz  DDG, Pessoa  ALS, França  GVA, et al.; Zika Embryopathy Task Force-Brazilian Society of Medical Genetics ZETF-SBGM. The phenotypic spectrum of congenital Zika syndrome. Am J Med Genet A. 2017;173:84157. DOIPubMedGoogle Scholar
  12. França  GVA, Schuler-Faccini  L, Oliveira  WK, Henriques  CMP, Carmo  EH, Pedi  VD, et al. Congenital Zika virus syndrome in Brazil: a case series of the first 1501 livebirths with complete investigation. Lancet. 2016;388:8917. DOIPubMedGoogle Scholar
  13. Rice  ME, Galang  RR, Roth  NM, Ellington  SR, Moore  CA, Valencia-Prado  M, et al. Vital signs: Zika-associated birth defects and neurodevelopmental abnormalities possibly associated with congenital Zika virus infection—U.S. territories and freely associated states, 2018. MMWR Morb Mortal Wkly Rep. 2018;67:85867. DOIPubMedGoogle Scholar
  14. Orioli  IM, Dolk  H, Lopez-Camelo  JS, Mattos  D, Poletta  FA, Dutra  MG, et al. Prevalence and clinical profile of microcephaly in South America pre-Zika, 2005-14: prevalence and case-control study. BMJ. 2017;359:j5018. DOIPubMedGoogle Scholar
  15. Costa Rica Bicentennial Government. First imported case of Zika in Costa Rica [in Spanish] [cited 2019 Aug 14].
  16. Ávalos  A. Pregnant woman becomes first native case of Zika in Costa Rica [in Spanish] [cited 2019 Aug 14].
  17. Chen  LH. Zika virus infection in a Massachusetts resident after travel to Costa Rica: a case report. Ann Intern Med. 2016;164:5746. DOIPubMedGoogle Scholar
  18. Ministerio de Salud de Costa Rica, Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud, Caja Costarricense del Seguro Social. Surveillance protocol for microcephaly and congenital syndrome associated with Zika virus in Costa Rica [in Spanish] [cited 2019 Sep 14].
  19. World Health Organization. Birth defects surveillance: a manual for programme managers [cited 2019 Sep 14].
  20. World Health Organization Multicentre Growth Reference Study Group. WHO child growth standards: methods and development [cited 2019 Aug 14].
  21. Centers for Disease Control and Prevention. CDC instructions for Zika MAC-ELISA protocol. 2018 Feb 2 [cited 2019 Aug 21].
  22. Benavides-Lara  A, Barboza-Arguello  MP. Abbreviated report of microcephaly cases reported to Costa Rican Birth Defects Register Center, Costa Rica 2011–2017 [in Spanish] [cited 2019 Aug 14].
  23. de Oliveira  WK, de França  GVA, Carmo  EH, Duncan  BB, de Souza Kuchenbecker  R, Schmidt  MI. Infection-related microcephaly after the 2015 and 2016 Zika virus outbreaks in Brazil: a surveillance-based analysis. Lancet. 2017;390:86170. DOIPubMedGoogle Scholar
  24. Smoots  AN, Olson  SM, Cragan  J, Delaney  A, Roth  NM, Godfred-Cato  S, et al. Population-based surveillance for birth defects potentially related to Zika virus infection—22 states and territories, January 2016–June 2017. MMWR Morb Mortal Wkly Rep. 2020;69:6771. DOIPubMedGoogle Scholar
  25. Besnard  M, Eyrolle-Guignot  D, Guillemette-Artur  P, Lastère  S, Bost-Bezeaud  F, Marcelis  L, et al. Congenital cerebral malformations and dysfunction in fetuses and newborns following the 2013 to 2014 Zika virus epidemic in French Polynesia. Euro Surveill. 2016;21:30181. DOIPubMedGoogle Scholar
  26. Honein  MA, Dawson  AL, Petersen  EE, Jones  AM, Lee  EH, Yazdy  MM, et al.; US Zika Pregnancy Registry Collaboration. Birth defects among fetuses and infants of US women with evidence of possible Zika virus infection during pregnancy. JAMA. 2017;317:5968. DOIPubMedGoogle Scholar
  27. Shapiro-Mendoza  CK, Rice  ME, Galang  RR, Fulton  AC, VanMaldeghem  K, Prado  MV, et al.; Zika Pregnancy and Infant Registries Working Group. Pregnancy outcomes after maternal Zika virus infection during pregnancy—U.S. Territories, January 1, 2016–April 25, 2017. MMWR Morb Mortal Wkly Rep. 2017;66:61521. DOIPubMedGoogle Scholar
  28. Cauchemez  S, Besnard  M, Bompard  P, Dub  T, Guillemette-Artur  P, Eyrolle-Guignot  D, et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet. 2016;387:212532. DOIPubMedGoogle Scholar
  29. Pacheco  O, Beltrán  M, Nelson  CA, Valencia  D, Tolosa  N, Farr  SL, et al. Zika virus disease in Colombia—preliminary report [cited 2019 Jun 14].
  30. Kleber de Oliveira  W, Cortez-Escalante  J, De Oliveira  WT, do Carmo  GM, Henriques  CMP, Coelho  GE, et al. Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed Zika virus transmission during the first trimester of pregnancy—Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:2427. DOIPubMedGoogle Scholar
  31. Marinho  F, de Araújo  VEM, Porto  DL, Ferreira  HL, Coelho  MRS, Lecca  RCR, et al. Microcephaly in Brazil: prevalence and characterization of cases from the Live Birth Information System (Sinasc), 2000–2015 [in Portuguese]. Epidemiol Serv Saude. 2016;25:70112. DOIPubMedGoogle Scholar
  32. Dufort  E, White  J. Pre-Zika microcephaly in Brazil: closer to the elusive baseline and new questions raised. Pediatrics. 2018;141:e20173811. DOIPubMedGoogle Scholar
  33. van der Linden  V, Pessoa  A, Dobyns  W, Barkovich  AJ, Júnior  HV, Filho  EL, et al. Description of 13 infants born during October 2015–January 2016 with congenital Zika virus infection without microcephaly at birth—Brazil. MMWR Morb Mortal Wkly Rep. 2016;65:13438. DOIPubMedGoogle Scholar
  34. Nithiyanantham  SF, Badawi  A. Maternal infection with Zika virus and prevalence of congenital disorders in infants: systematic review and meta-analysis. Can J Public Health. 2019;110:63848. DOIPubMedGoogle Scholar
  35. de Paula Freitas  B, Zin  A, Ko  A, Maia  M, Ventura  CV, Belfort  R Jr. Anterior-segment ocular findings and microphthalmia in congenital Zika syndrome. Ophthalmology. 2017;124:18768. DOIPubMedGoogle Scholar
  36. Zin  AA, Tsui  I, Rossetto  J, Vasconcelos  Z, Adachi  K, Valderramos  S, et al. Screening criteria for ophthalmic manifestations of congenital Zika virus infection. JAMA Pediatr. 2017;171:84754. DOIPubMedGoogle Scholar
  37. Leal  MC, Muniz  LF, Ferreira  TSA, Santos  CM, Almeida  LC, Van Der Linden  V, et al. Hearing loss in Infants with microcephaly and evidence of congenital Zika virus infection—Brazil, November 2015–May 2016. MMWR Morb Mortal Wkly Rep. 2016;65:9179. DOIPubMedGoogle Scholar
  38. de Fatima Vasco Aragao  M, van der Linden  V, Brainer-Lima  AM, Coeli  RR, Rocha  MA, Sobral da Silva  P, et al. Clinical features and neuroimaging (CT and MRI) findings in presumed Zika virus related congenital infection and microcephaly: retrospective case series study. BMJ. 2016;353:i1901. DOIPubMedGoogle Scholar
  39. Wheeler  AC. Development of infants with congenital Zika syndrome: what do we know and what can we expect? Pediatrics. 2018;141(Suppl 2):S15460. DOIPubMedGoogle Scholar
  40. Tinker  SC, Gilboa  S, Reefhuis  J, Jenkins  MM, Schaeffer  M, Moore  CA. Challenges in studying modifiable risk factors for birth defects. Curr Epidemiol Rep. 2015;2:2330. DOIPubMedGoogle Scholar
  41. Singh  RK, Dhama  K, Karthik  K, Tiwari  R, Khandia  R, Munjal  A, et al. Advances in diagnosis, surveillance, and monitoring of Zika virus: an update. Front Microbiol. 2018;8:2677. DOIPubMedGoogle Scholar
  42. Adebanjo  T, Godfred-Cato  S, Viens  L, Fischer  M, Staples  JE, Kuhnert-Tallman  W, et al.; Contributors. Update: interim guidance for the diagnosis, evaluation, and management of infants with possible congenital Zika virus infection—United States, October 2017. MMWR Morb Mortal Wkly Rep. 2017;66:108999. DOIPubMedGoogle Scholar
  43. Eppes  C, Rac  M, Dunn  J, Versalovic  J, Murray  KO, Suter  MA, et al. Testing for Zika virus infection in pregnancy: key concepts to deal with an emerging epidemic. Am J Obstet Gynecol. 2017;216:20925. DOIPubMedGoogle Scholar
  44. Pan American Health Organization. Guidelines for surveillance of Zika virus disease and its complications. 2018 edition [cited 2019 Aug 5].
  45. Gilboa  SM, Mai  CT, Shapiro-Mendoza  CK, Cragan  JD, Moore  CA, Meaney-Delman  DM, et al. Population-based pregnancy and birth defects surveillance in the era of Zika virus. Birth Defects Res. 2017;109:3728. DOIPubMedGoogle Scholar




Follow Up

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing medical education (CME) credit, please go to Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.

You must be a registered user on If you are not registered on, please click on the “Register” link on the right hand side of the website.

Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to view and/or print your certificate. For questions regarding this activity, contact the accredited provider, For technical assistance, contact American Medical Association’s Physician’s Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please go to The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national medical association for review.

Article Title: 
Zika Virus–Associated Birth Defects, Costa Rica, 2016–2018
CME Questions
  • Your patient is a newborn infant born to a mother with confirmed Zika virus (ZIKV) infection. According to the descriptive analysis by Benavides-Lara and colleagues, which of the following statements about prevalence of Zika-related birth defects (ZBD) and microcephaly among live-born infants in Costa Rica, March 2016 to March 2018, is correct?

    • Prevalence of ZBD was 5.3/100,000 births

    • Mortality within the first year of life among infants with ZBD was 6.6%

    • Provinces with the highest prevalence of ZBD were Limón and Puntarenas (58.8/100,000 and 37.1/100,000 live births, respectively)

    • Three-quarters of infants with confirmed or probable ZBD had microcephaly

  • According to the descriptive analysis by Benavides-Lara and colleagues, which of the following statements about clinical and test findings of live-born infants with ZBD in Costa Rica, March 2016 to March 2018, is correct?

    • 82% had brain anomalies; 95%, neurodevelopmental abnormalities; 41%, eye abnormalities; and 9% had hearing loss

    • Half of the evaluated cases had evidence of ≥1 brain defect on neuroimaging

    • Most cases were hypotonic

    • None of the cases had swallowing problems

  • According to the descriptive analysis by Benavides-Lara and colleagues, which of the following statements about clinical and public health implications of ZBD among live-born infants in Costa Rica, March 2016 to March 2018, is correct?

    • Timing of ZBD in Costa Rica relative to peak incidence of ZIKV infection in pregnant women differed substantially from that in Brazil, Colombia, and the United States

    • Enhancement of existing national birth defects surveillance identified affected babies and ensured referral of families to appropriate services

    • After ZIKV infection in a pregnant woman, microcephaly is the only congenital anomaly that should be monitored, and monitoring can stop at birth

    • Costa Rica’s National Guidelines (CRNG) regarding surveillance of ZIKV disease in pregnant women contradict those of the Pan American Health Organization (PAHO)


Cite This Article

DOI: 10.3201/eid2702.202047

Original Publication Date: January 21, 2021

Related Links

Table of Contents – Volume 27, Number 2—February 2021

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Adriana Benavides-Lara, Costa Rican Birth Defects Register Center, Costa Rican Institute of Research and Education in Nutrition and Health, Cartago, Costa Rica

Send To

10000 character(s) remaining.


Page created: December 07, 2020
Page updated: January 21, 2021
Page reviewed: January 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.